Insmed Incorporated (NASDAQ:INSM) Receives $93.93 Consensus PT from Brokerages

Insmed Incorporated (NASDAQ:INSM) has earned a consensus recommendation of “Buy” from the seventeen analysts that are currently covering the stock, Marketbeat Ratings reports. Seventeen analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $94.63.

INSM has been the subject of a number of analyst reports. Wells Fargo & Company raised their price objective on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Truist Financial lifted their target price on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Royal Bank of Canada reiterated an “outperform” rating and set a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Monday.

Insmed Stock Performance

Shares of INSM stock opened at $65.61 on Monday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock has a fifty day moving average of $71.99 and a 200 day moving average of $73.21. The firm has a market capitalization of $11.93 billion, a price-to-earnings ratio of -11.74 and a beta of 0.84. Insmed has a 52 week low of $21.92 and a 52 week high of $84.91.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $92.82 million during the quarter, compared to analysts’ expectations of $91.63 million. During the same period in the previous year, the company earned ($1.06) earnings per share. Insmed’s revenue for the quarter was up 22.9% on a year-over-year basis. As a group, research analysts expect that Insmed will post -4.56 earnings per share for the current year.

Insiders Place Their Bets

In other Insmed news, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the transaction, the chief financial officer now owns 118,863 shares of the company’s stock, valued at $9,545,887.53. The trade was a 13.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 6,830 shares of the company’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $72.57, for a total transaction of $495,653.10. Following the completion of the transaction, the chief executive officer now owns 233,924 shares of the company’s stock, valued at approximately $16,975,864.68. The trade was a 2.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 88,232 shares of company stock worth $6,868,473. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of INSM. Cullen Frost Bankers Inc. grew its position in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 221 shares in the last quarter. Elequin Capital LP purchased a new stake in Insmed in the 4th quarter worth $28,000. Steward Partners Investment Advisory LLC boosted its holdings in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares during the last quarter. NBC Securities Inc. purchased a new position in shares of Insmed during the first quarter valued at about $49,000. Finally, V Square Quantitative Management LLC lifted its position in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.